α-Synuclein oligomerization: A role for lipids?

Trends in Neurosciences

Volumn 26, Issue 10, 2003, Pages 517-519

  Welch, Kevin ^a   Yuan, Junying ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; FATTY ACID; LIPID; OLIGOMER;

DEGENERATIVE DISEASE; HUMAN; MISSENSE MUTATION; NEUROPATHOLOGY; NEUROTOXICITY; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SHORT SURVEY;

EID: 0141867848     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2003.08.001     Document Type: Short Survey

References (20)

1. Goedert M. α-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2:2001;492-501.
2. Goldberg M., Lansbury P. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2:2000;E115-E119.
3. Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:2003;486-489.
4. Bucciantini M., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511.
5. Walsh D., et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
6. Lashuel H., et al. Amyloid pores from pathogenic mutations. Nature. 418:2002;291.
7. Volles M., Lansbury P. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 41:2002;4595-4602.
8. Gosavi N., et al. Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277:2002;48984-48992.
9. Souza J., et al. Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275:2000;18344-18349.
10. Conway K., et al. Kinetic stabilization of the a-synuclein protofibril by a dopamine-α-synuclein adduct. Science. 294:2001;1346-1349.
11. Yamin G., et al. Nitration inhibits fibrillation of human α-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 542:2003;147-152.
12. Davidson W., et al. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273:1998;9443-9449.
13. Sharon R., et al. α-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9110-9115.
14. Sharon R., et al. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 37:2003;583-595.
15. Lippa C., et al. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153:1998;1365-1370.
16. Dickson D., et al. Widespread alterations of α-synuclein in multiple system atrophy. Am. J. Pathol. 155:1999;1241-1251.
17. Glatz J., Veerkamp J. A radiochemical procedure for the assay of fatty acid-binding proteins. Anal. Biochem. 132:1983;89-95.
18. Perrin R., et al. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276:2001;41958-41962.
19. 1B-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. J. Neurochem. 83:2002;623-634.
20. Xu J., et al. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med. 8:2002;600-606.